◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › R › RCKT

Rocket Pharmaceuticals, Inc. - (RCKT) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

NASDAQ · DATA UPDATED 2026-10-08

Rocket Pharmaceuticals, Inc. - (RCKT) operates in the NASDAQ industry and is headquartered in Cranbury, United States with about 202 employees. Its market capitalization is roughly $268 million. In the fiscal year ended 2025-12-31, RCKT reported $0M in revenue and ($223M) in net income.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States.

Interactive charts & full statements →

RCKT Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Total Revenue	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—
Gross Profit	—	($11M)	($9M)	($7M)	($6M)	($5M)	($1M)	$0M	$0M	$0M	$0M	$0M	$0M	—	—
Gross Margin %	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Operating Income (EBIT)	($192M)	($229M)	($273M)	($260M)	($224M)	($167M)	($136M)	($76M)	($71M)	($27M)	($42M)	($20M)	($8M)	($7M)	($6M)
Operating Margin %	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Net Income	($17M)	($223M)	($259M)	($246M)	($222M)	($169M)	($147M)	($83M)	($75M)	($29M)	($43M)	($68M)	($10M)	($8M)	($6M)
Net Margin %	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
EBITDA	$8M	($210M)	($247M)	($237M)	($214M)	($158M)	($132M)	($71M)	($71M)	($27M)	($41M)	($20M)	($8M)	($7M)	($6M)
Earnings Per Share (EPS)	$-0.18	$-2.01	$-2.73	$-2.92	$-3.26	$-2.67	$-2.65	$-1.70	$-1.89	$-4.36	$-6.41	$-10.29	$-4.53	$-3.62	$-2.88
Shares Outstanding (M)	115M	111M	95M	84M	68M	63M	55M	49M	—	7M	7M	7M	2M	2M	2M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RCKT Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$0M	$0M	$0M	$0M	$0M	$0M	$9M	$0M
Gross Profit	—	($2M)	—	—	($3M)	($3M)	$5M	($2M)
Gross Margin %	—	—	—	—	—	—	50.0%	—
Operating Income (EBIT)	($47M)	($49M)	($44M)	($52M)	($71M)	($64M)	($63M)	($69M)
Operating Margin %	—	—	—	—	—	—	-682.5%	—
Net Income	$123M	($48M)	($43M)	($50M)	($69M)	($61M)	($60M)	($67M)
Net Margin %	—	—	—	—	—	—	-656.7%	—
EBITDA	$137M	($45M)	($37M)	($47M)	($66M)	($58M)	($57M)	($64M)
Earnings Per Share (EPS)	$1.08	$-0.42	$-0.38	$-0.45	$-0.62	$-0.56	$-0.62	$-0.71
Shares Outstanding (M)	115M	112M	111M	112M	111M	110M	98M	94M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RCKT Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Cash from Operations (CFO)	($170M)	($190M)	($210M)	($195M)	($178M)	($121M)	($75M)	($65M)	($54M)	($26M)	($37M)	($17M)	($10M)	($6M)	($7M)
Capital Expenditures (CapEx)	$0M	$0M	$6M	$16M	$9M	$8M	$29M	$23M	$1M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($171M)	($190M)	($216M)	($211M)	($187M)	($129M)	($104M)	($88M)	($55M)	($26M)	($38M)	($18M)	($10M)	($6M)	($7M)
FCF Margin %	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Dividends Paid	—	—	—	—	$0M	—	$6M	—	—	$0M	$0M	$0M	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RCKT Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($40M)	($45M)	($35M)	($50M)	($49M)	($56M)	($47M)	($52M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$2M
Free Cash Flow (FCF)	($40M)	($45M)	($35M)	($50M)	($49M)	($56M)	($47M)	($54M)
FCF Margin %	—	—	—	—	—	—	-514.5%	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RCKT Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Total Assets	$423M	$330M	$528M	$566M	$552M	$497M	$591M	$372M	$251M	$102M	$130M	$113M	$6M	$13M	$1M
Cash & Cash Equivalents	$225M	$78M	$164M	$56M	$141M	$233M	$297M	$185M	$111M	$79M	$30M	$80M	$4M	$13M	$1M
Total Liabilities	$54M	$53M	$64M	$74M	$62M	$42M	$87M	$65M	$57M	$54M	$56M	$5M	$57M	$52M	$32M
Total Debt (Short + Long-Term)	$3M	$3M	$3M	$3M	$3M	$3M	$42M	$46M	$41M	$50M	$49M	$0M	$8M	$1M	$2M
Total Shareholders' Equity	$369M	$277M	$463M	$493M	$490M	$455M	$504M	$307M	$194M	$48M	$73M	$109M	($52M)	($39M)	($31M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RCKT viewer.

Other Companies in Software & IT Services

RBBN · Ribbon Communications Inc. - — $278 million
YOUNI · Younited Financial S.A. — €275 million
ARQQ · Arqit Quantum Inc. - — $274 million
TDUP · ThredUp Inc. - — $273 million
FACT · FACT II Acquisition Corp — $260 million
LDI · loanDepot, Inc. — $257 million
EVMN · Evommune, Inc. — $244 million
AIV · Apartment Investment and Management Company — $242 million

← RCI.B All “R” companies RCKY →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.